#United States #Redwood City, California #Codexis #Nitto Denko #ECO Synthesis

Codexis Collaborates with Nitto Denko Pouring New Life into RNA Therapeutics Manufacturing

In a move that promises to reshape the landscape of therapeutic manufacturing, Codexis, Inc. (NASDAQ: CDXS) has entered into an evaluation agreement with Nitto Denko Avecia, Inc. This landmark collaboration aims to explore the capabilities of Codexis's innovative ECO Synthesis® Manufacturing Platform, which offers a distinctive enzyme-catalyzed approach to producing therapeutic small interfering RNA (siRNA) products, replacing outdated solid-phase synthesis methods.

A New Era for siRNA Manufacturing

The evolution of RNA therapeutics has provided significant opportunities for treating a variety of diseases, from genetic disorders to cancers. However, traditional production methods often struggle with scalability and efficiency. Codexis steps in with its ECOSynthesis® platform, which uses enzymatic processes to streamline siRNA manufacturing—leading to faster, more cost-effective production runs. This platform is designed with an adaptable framework allowing manufacturers to scale operations while maintaining product quality.

Stephen Dilly, the CEO of Codexis, expressed enthusiasm about the partnership, stating, "This collaboration represents a significant milestone toward expanding the reach of our ECO Synthesis® Manufacturing Platform, through best-in-class CDMO collaborations." The partnership with Nitto Denko, recognized for its leadership in oligonucleotide therapeutic manufacturing, allows Codexis to leverage Nitto’s extensive experience and infrastructure.

Nitto Denko's Commitment to Innovation

Nitto Denko Avecia is a well-respected contract development and manufacturing organization (CDMO) specializing in the production of oligonucleotide therapeutics. Tammy Cooper, President at Nitto Denko Avecia, emphasized the alignment of their mission with Codexis's innovative technologies. She noted, "Exploring Codexis's ECO Synthesis® reflects our commitment to pioneering next-generation technologies that can redefine scalability, sustainability, and innovation in therapeutic development."

The evaluation agreement signifies an opening for broader licensing discussions that could lead to wider adoption of the ECO Synthesis® technology across the industry, potentially driving down production costs and enhancing accessibility for patients worldwide.

Advantages of the ECO Synthesis® Platform

The ECO Synthesis® Manufacturing Platform stands out due to its enzyme-catalyzed approach, which offers:

• - Scalability: Easily adjustable processes to cater to varying production demands.
• - Efficiency: Streamlined techniques that shorten production timelines and lower costs.
• - Sustainability: Reduced waste generation and energy consumption compared to traditional methods.

These advantages position Codexis at the forefront of industrial biotechnology when it comes to producing highly effective therapeutics on a larger scale. With more than 1,500 successful oligonucleotide sequences under its belt, Nitto Denko Avecia’s expertise complements Codexis's pioneering platform perfectly, creating a powerful alliance in therapeutic development.

The Future Landscape of Therapeutic Manufacturing

As the field of therapeutics continues to advance rapidly, the implications of this collaboration could be monumental. If the ECO Synthesis® platform proves successful through Nitto Denko's evaluations, it may inspire a paradigm shift in how siRNA therapies are developed, manufactured, and delivered. This collaboration underlies a growing trend within the biopharmaceutical industry to embrace greener, more sustainable manufacturing processes.

In conclusion, the partnership between Codexis and Nitto Denko Avecia emphasizes a shared vision: to enhance the accessibility and efficiency of therapeutics while innovating the manufacturing landscape for RNA-based treatments. As these companies move forward, they pave the way for a new era of healthcare solutions that prioritize patient outcomes and environmental responsibility. For further information about Codexis, visit www.codexis.com, and for Nitto Denko Avecia, visit www.Avecia.com.